Back to top
more

Amgen (AMGN)

(Delayed Data from NSDQ)

$296.88 USD

296.88
2,410,872

+1.78 (0.60%)

Updated Aug 1, 2025 04:00 PM ET

After-Market: $296.81 -0.07 (-0.02%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.75%
2Buy17.82%
3Hold9.58%
4Sell5.28%
5Strong Sell2.61%
S&P50011.30%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

  • Value Score A
  • Growth Score A
  • Momentum Score A
  • VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

B Value B Growth D Momentum B VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Bottom 42% (143 out of 246)

Industry: Medical - Biomedical and Genetics

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Zacks News

Thousand Oaks, CA-based Amgen is one of the biggest biotech companies in the world, with a strong presence in the oncology/hematology, cardiovascular disease, neuroscience, inflammation, bone health and nephrology markets. The company used advances in cellular and molecular biology to develop two of the biotech industry’s earliest and most successful drugs, Epogen (anemia) and Neupogen (white blood cell stimulant). Amgen successfully launched two next-generation products, Aranesp and Neulasta. Meanwhile, the acquisition of Immunex Corporation gave Amgen access to the multi-blockbuster drug, Enbrel. However, all these older drugs are facing declining sales due to biosimilar or branded competition, which is being somewhat offset by its newer blockbuster drugs like Prolia/Xgeva

Zacks Equity Research

Allergan (AGN) Q2 Earnings & Sales Top, Restasis Sales Down

by Zacks Equity Research

Allergan plc (AGN) beat estimates for both earnings and sales in Q2. The company raised its 2017 outlook. Shares were down slightly in pre-market trading.

    Zacks Equity Research

    Pfizer (PFE) Surpasses Q2 Earnings Estimates, Misses Sales

    by Zacks Equity Research

    Pfizer, Inc. (PFE) beat expectations for earnings while missing the same for sales in Q2. It raised the lower end of its 2017 adjusted earnings guidance but kept the revenue expectations intact.

      Zacks Equity Research

      Sanofi (SNY) Q2 Earnings In Line, Sales Lag,'17 View Raised

      by Zacks Equity Research

      Sanofi (SNY) Q2 results were mixed as it reported in-line earnings and slightly missed sales expectations. However, the company raised its 2017 earnings guidance.

        Zacks Equity Research

        Company News for July 27, 2017

        by Zacks Equity Research

        Companies in the news are: AMD,ANTM,KO,AMGN

          Zacks Equity Research

          Amgen (AMGN) Stock Falls Despite Q2 Earnings & Sales Beat

          by Zacks Equity Research

          Amgen Inc. (AMGN) beat estimates on both earnings & sales in Q2. While Amgen slightly tightened the sales guidance, it raised the earnings outlook backed by its strong performance in the first half.

            Arpita Dutt headshot

            Biotech Stock Roundup: Amgen, Biogen Top Q2 Estimates, Update on Incyte RA Drug

            by Arpita Dutt

            Earnings season kicked off on a positive note for biotech stocks with big players like Amgen (AMGN) and Biogen reporting better than expected results.

              Zacks Equity Research

              Biogen (BIIB) Tops Q2 Earnings & Sales, Spinraza Sales Up

              by Zacks Equity Research

              Biogen Inc. (BIIB) surpassed expectations both for earnings and sales in the second quarter of 2017. The MS drugmaker also raised its revenue guidance for 2017 on the back of strong Spinraza sales.

                Zacks Equity Research

                Big Pharma Q2 Earnings Releases on Jul 25: LLY, BIIB, AMGN

                by Zacks Equity Research

                Three pharma giants are set to report second-quarter results on Jul 25. Let's see how things are shaping up for this quarter.

                  Zacks Equity Research

                  Amgen (AMGN) to Report Q2 Earnings: What's in the Cards?

                  by Zacks Equity Research

                  While Amgen, Inc.'s (AMGN) growth drugs like Prolia & Xgeva might continue to do well. Biosimilar competition and slowdown in sales of mature products can put pressure on sales growth.

                    Arpita Dutt headshot

                    Biotech Stock Roundup: Vertex Boosted by CF Data, FDA Nod for Gilead, Puma Drugs

                    by Arpita Dutt

                    Vertex (VRTX) got a significant boost with positive data from its cystic fibrosis (CF) pipeline while quite a few companies provided regulatory updates.

                      Zacks Equity Research

                      Ligand Signs Agreement with Amgen, Grants Rights to Captisol

                      by Zacks Equity Research

                      Ligand Pharmaceuticals Incorporated (LGND) announced that it has signed a commercial license and supply agreement with Amgen Inc. granting exclusive worldwide rights to use Ligand's Captisol technology for the development of AMG 330

                        Zacks Equity Research

                        Novartis Tops Q2 Earnings, Sandoz Faces Pricing Pressure

                        by Zacks Equity Research

                        Novartis AG (NVS) reported second-quarter 2017 core earnings of $1.22 per share, beating the Zacks Consensus Estimate of $1.16 but the recorded figure was a penny lower than the year-ago figure of $1.23.

                          Ryan McQueeney headshot

                          Why Did Radius Health (RDUS) Stock Plummet Today?

                          by Ryan McQueeney

                          Shares of Radius Health (RDUS) dropped more than 7.8% in early morning trading hours Monday after the company announced that Jesper Hoiland, a former top-ranking executive at Novo Nordisk (NVO), has been appointed its new president and chief executive officer.

                            Zacks Equity Research

                            Mylan's Biosimilar Herceptin Gets FDA Advisory Committee Nod

                            by Zacks Equity Research

                            Mylan N.V. (MYL) and partner, Biocon Ltd. announced that the FDA Oncologic Drugs Advisory Committee (ODAC) unanimously recommended approval of its biosimilar version of Roche's (RHHBY) breast cancer drug Herceptin (trastuzumab).

                              Zacks Equity Research

                              Amgen (AMGN) Gets CRL for Osteoporosis Drug Evenity's BLA

                              by Zacks Equity Research

                              Amgen Inc. (AMGN) and partner UCB SA (UCBJF) announced that the FDA has issued a complete response letter (CRL) for the biologics license application (BLA) for Evenity (romosozumab).

                                Zacks Equity Research

                                Can Novartis (NVS) Spring a Surprise This Earnings Season?

                                by Zacks Equity Research

                                Swiss pharmaceutical company Novartis AG (NVS) is scheduled to report second-quarter 2017 results on Jul 18.

                                  Zacks Equity Research

                                  Can ImmunoGen's Lead Pipeline Cancer Candidate Boost Growth?

                                  by Zacks Equity Research

                                  On Jul 12, 2017, we issued an updated report on ImmunoGen, Inc. (IMGN).

                                    Zacks Equity Research

                                    Amgen's Myeloma Drug Improves Overall Survival in Phase III

                                    by Zacks Equity Research

                                    Biotech major, Amgen, Inc. (AMGN) announced final data from the phase III ASPIRE study, which showed that a combination regimen of its drug, Kyprolis, significantly improved overall survival (OS) in patients with relapsed multiple myeloma.

                                      Zacks Equity Research

                                      Amgen Gets FDA Nod to Broaden Leukemia Drug Blincyto's Label

                                      by Zacks Equity Research

                                      Amgen Inc. (AMGN) announced that its supplemental biologics license application (sBLA) to convert accelerated approval for leukemia drug Blincyto to regular approval has been approved by the FDA.

                                        Arpita Dutt headshot

                                        Biotech Stock Roundup: Arena Shoots Up on Study Data, CELG Inks Immuno-Oncology Deal

                                        by Arpita Dutt

                                        Arena (ARNA) saw it shares shoot up on mid-stage data on its pulmonary arterial hypertension drug while quite a few companies provided regulatory updates.

                                          Zacks Equity Research

                                          Are Medicines Company's Key Drugs Set for Growth in 2017?

                                          by Zacks Equity Research

                                          On Jul 7, 2017, we issued an updated report on The Medicines Company (MDCO).

                                            Zacks Equity Research

                                            Novartis' Cosentyx Superior to Stelara in Psoriasis Study

                                            by Zacks Equity Research

                                            Novartis' (NVS) psoriasis drug Cosentyx got a label update from the Committee for Medicinal Products for Human Use (CHMP) in the EU,

                                              Zacks Equity Research

                                              Merck Falls as FDA Puts Hold on 3 Keytruda Myeloma Studies

                                              by Zacks Equity Research

                                              Merck & Co., Inc. (MRK) shares were down more than 1% in after-hours trading on Wednesday after the company announced that the FDA has placed a clinical hold on three combination studies of Keytruda in multiple myeloma, a form of blood cancer.

                                                Arpita Dutt headshot

                                                Biotech Stock Roundup: Cara Plunges on Study Data, Regulatory Updates & More

                                                by Arpita Dutt

                                                Key highlights in the biotech sector include mixed data from Cara (CARA) and regulatory updates from companies like BioMarin.

                                                  Zacks Equity Research

                                                  Pfizer's (PFE) Leukemia Candidate Receives Approval in EU

                                                  by Zacks Equity Research

                                                  Pfizer Inc. (PFE) announced that its leukemia candidate, Besponsa, has been approved by the European Commission.